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Abstract  
Context 
Cachexia is commonly found in cancer patients and has profound consequences yet there is only one 
questionnaire that examines the patient’s perspective. 
Objective 
To report a rigorously developed module for patient self-reported impact of cancer cachexia.  
Methods 
Module development followed published guidelines. Patients from across the cancer cachexia 
trajectory were included. In Phase 1, HRQOL issues were generated from a literature review and 
interviews with patients in four countries. The issues were revised based on patient and health care 
professional (HCP) input. In Phase 2, questionnaire items were formulated and translated into the 
languages required for Phase 3, the pilot phase, in which patients from eight countries scored the 
relevance and importance of each item, and provided qualitative feedback. 
Results 
A total of 39 patients and 12 HCPs took part in Phase 1. The literature review produced 68 HRQOL 
issues, with 22 new issues arising from the patient interviews. Following patient and HCP input, 44 
issues were formulated into questionnaire items in Phase 2. 110 patients took part in Phase 3. One 
item was reworded and 20 items were deleted as a consequence of patient feedback.   
Conclusions 
The QLQ-CAX24 is a cancer cachexia-specific questionnaire, comprising 24 items, for HRQOL 
assessment in clinical trials and in practice. It contains five multi-item scales (food aversion, eating 
and weight-loss worry, eating difficulties, loss of control and physical decline) and four single items. 
 
Keywords 
Cachexia; quality of life; palliative care; patient outcome assessment 
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Background 
Cancer cachexia is a multidimensional syndrome characterised by involuntary weight loss, at least 
partly attributable to muscle atrophy, which leads to progressive functional impairment (1) (see 
Figure 1). It has a profound negative outcome on treatment, survival, clinical burden and 
psychosocial factors yet there are currently no standard of care or approved drug treatments. The 
incidence of cachexia among cancer patients is approximately 50-80% and cachexia accounts for up 
to 20% of cancer deaths (2). Cachexia is therefore a common problem for cancer patients which has 
serious consequences. 
Insert Fig 1 about here 
Patient reported outcome (PRO) measures, which provide a measure of patients’ health from the 
perspective of the patient, can improve routine clinical practice (3). Health-related quality of life 
(HRQOL) is a PRO concerned with those aspects of quality of life which patients consider are affected 
by disease and treatment (4). Evaluating HRQOL is particularly important in conditions like cancer 
cachexia when disease outcome measures, such as survival, are an inappropriate assessment of 
treatment success. A validated HRQOL assessment tool is vital for the assessment of new 
treatments.  
Where a patient lies on the cachexia continuum and the extent of primary and secondary cachexia 
are crucial clinical considerations and it is important that an HRQOL instrument is applicable to the 
full range of cancer patients with cachexia (5). Primary cachexia refers to the tumour-induced 
metabolic component of the condition and in secondary cachexia, secondary nutritional impact 
symptoms (S-NIS) contribute to the progression of the primary cachexia (6, 7). S-NIS are factors 
which interfere with nutritional intake, some of which are treatable using supportive care measures 
(8-10).  
HRQOL is an essential component in the evaluation of therapeutic interventions for cachexia 
because patients must perceive a benefit if a treatment is to be considered successful (7). Clinical 
decisions should partly be based on the impact of treatment on HRQOL (11). Therefore an 
instrument is required to measure the HRQOL effects of cachexia from diagnosis, through treatment 
and beyond. The only currently available cancer cachexia specific instrument, the Functional 
Assessment of Anorexia/Cachexia Therapy (FAACT) (12-15), is part of the Functional Assessment of 
Chronic Illness Therapy (FACIT) measurement system. The European Organisation for the Research 
and Treatment of Cancer (EORTC) provides an alternative measurement system with the core 
instrument, the QLQ-C30, widely used to measure HRQOL in patients with cancer (16, 17). This paper 
4 
 
describes the development of a questionnaire module to supplement the EORTC QLQ-C30  to 
provide a comprehensive assessment of HRQOL in patients with cancer cachexia. 
 
 
Methods  
The development of EORTC Quality of Life Group modules follows four phases (18). In Phase 1, 
HRQOL issues are generated through interviews with patients and health care professionals (HCPs), 
and a literature search. These HRQOL issues are reviewed and revised in Phase 2 and questionnaire 
items are formulated. In Phase 3, the questionnaire items are pilot tested and a provisional version 
of the module is developed. In Phase 4 the new module is field tested. The work reported here 
describes Phases1-3. The study protocol was approved by the EORTC Quality of Life Group. Ethical 
and research governance approvals were obtained at each centre in accordance with local 
requirements and all patients provided written informed consent. The study was coordinated from 
Southampton, UK with additional centres in France, Germany, Greece, Italy, Norway, Poland, 
Sweden and Switzerland. Collaborator meetings were held every six months, with regular email 
discussion and teleconferences between these times. 
Participants 
Eligible patients had a confirmed cancer diagnosis and met the consensus definition of cancer 
cachexia (1). A 2x2 recruitment matrix was used for Phase 1 with patients categorised according to 
cachexia stage (syndrome vs. refractory cachexia) and many or few  S-NIS, as assessed by the local 
researcher (Table 1). Patients with many S-NIS were required to have been treated for these 
symptoms for at least two weeks. 
For the Phase 3 interviews, the recruitment matrix became 3x2. Patients with an ECOG performance 
status (19) of 3 or 4 were classified as refractory cachexia. The remaining patients were divided into 
those with a relatively recent cancer diagnosis (within the first 100 days) and those who had been 
diagnosed more than 100 days prior to the interview. Scores on the Symptom Checklist (see section 
Phase 3: Testing the questionnaire for relevance and acceptability) were used to categorise patients 
into those with fewer S-NIS symptoms (Group A) and more S-NIS symptoms (Group B).   
All participants were 18 years or over. Patients unable to take part in interviews and complete self-
report questionnaires were excluded. 
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Phase 1: Generation of relevant HRQOL issues 
A comprehensive systematic review of the literature review was carried out to generate an initial list 
of HRQOL issues (20). Semi-structured interviews (Phase 1a interviews), in which patients were 
asked to describe their experience of weight loss, were conducted in four countries (Italy, Norway, 
Switzerland, UK) to identify novel issues. Interviews were carried out until data saturation was 
achieved, defined as when three  consecutive interviews produced no new issues (21). The issues 
generated in the patient interviews were added to those already collected in the literature review. 
The list of issues was distributed to the project collaborators for feedback and to check for missing 
issues. This led to the combination of some issues, modifications, and removal of issues with obvious 
overlap with the EORTC QLQ-C30. The revised list was used in a second round of patient interviews 
(Phase 1b interviews) and also interviews with HCPs who were all experienced in cancer cachexia. 
Interviewees rated the importance of each issue on a four point scale ranging from not at all (1 
point) to very much (4 points) and identified any issues that should not be included. Finally, 
participants were asked to consider whether any issues were missing.  
Phase 2: Construction of the provisional questionnaire 
EORTC guidelines were followed to determine which issues should be removed and whether any 
new issues should be added to the list (18). Issues were operationalised into items with a response 
format and time frame compatible with the EORTC QLQ-C30. The EORTC QLG item bank, an 
unpublished weight loss and eating habits questionnaire which had been used in several Macmillan 
trials and the FAACT were consulted to help create the items. Items were then translated into all the 
languages required for Phase 3, following the EORTC translation procedure guidelines(22). 
Phase 3: Testing the questionnaire for relevance and acceptability 
The provisional questionnaire was piloted with patients in eight European countries: France, 
Germany, Greece, Italy, Norway, Poland, Sweden and the UK. After providing informed consent, 
patients completed the EORTC QLQ-C30 followed by the provisional questionnaire. For each item on 
the provisional questionnaire, patients were asked to indicate relevance (yes or no) and importance 
(not at all, a little, quite a bit, very much). They were encouraged to “think aloud” during this 
process, to indicate if they found any question difficult, annoying, confusing, upsetting or intrusive, 
and to make any other comment. Sociodemographic and clinical data were recorded, along with the 
Charlson Comorbidity Index(23), Eastern Cooperative Oncology Group (ECOG) Common Toxicity 
Criteria and ECOG Performance Status (19). Finally, the patients completed the Symptom Checklist, a 
measure of S-NIS. This checklist combines items from the Patient-Generated Subjective Global 
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Assessment (24)  and the Nutrition Impact Symptoms Checklist (10) to produce a checklist of 17 
items which is applicable to patients with any type of cancer (Figure 2). Patients with a scaled score 
of below 25 on the Symptom Checklist were assigned to Group A (few S-NIS symptoms) whereas 
patients scoring above 25 were assigned to Group B (more S-NIS symptoms). 
Insert Fig 2 about here 
The number of items in the questionnaire was reduced by application of decision rules from the 
module development guidelines (18). 
The HRQOL review (20) informed the scales for the new module and multitrait scaling was used to 
examine whether the hypothesised scales demonstrated convergent validity i.e. whether each item 
within the scale correlated ≥0.4 (corrected for overlap) with its own hypothesised scale (25).The 
internal consistency of the scales was tested using Cronbach’s alpha. A Cronbach’s alpha of ≥0.70 is 
often considered to provide evidence of adequate internal consistency (25). Analyses were carried 
out using Stata Statistical Software, release 13 (26). 
Results 
Module development is summarised in Figure 3.  
Insert Fig 3 about here 
Phase 1 
The systematic literature review (20) identified 18 relevant papers, from which 68 HRQOL issues 
were extracted. Twenty one patient interviews were required to achieve data saturation. Analysis of 
these interviews identified 22 new issues, resulting in a total of 90 issues. The characteristics of the 
patients who participated in Phase 1a are shown in Table 1.  
The original 90 issues were reduced to 50 following review for repetition and overlap with the 
EORTC QLQ-C30. These issues were reviewed by eighteen patients from three countries (UK, Norway 
and Italy) and 12 HCPs (including palliative care doctors and nurses, dietitians and oncologists) from 
Norway, Italy, Switzerland and the UK. 
Phase 2 
Comments from patients and HCPs led to the inclusion of items being too tired to eat and being in 
too much pain to eat. Thirteen issues were removed as a result of the decision rules (n=9), because it 
was not clear whether these were positive or negative in terms of HRQOL (n=2) or because they 
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were not patient reported outcomes (n=2). One issue, ‘strong negative reaction to food’ became 
three items to distinguish whether the negative reaction was due to the thought, smell or sight of 
food. ‘Embarrassed by eating or weight loss’ became two items to differentiate the two sources of 
embarrassment. As a result of all these modifications, the questionnaire for Phase 3 comprised a 
total of 44 items.  
Phase 3 
A total of 110 patients was recruited (Table 2).  
Insert Table 2 about here 
The characteristics of the patients taking part in this phase are shown in Table 3. Group A (low 
Symptom Checklist score) and Group B (high Symptom Checklist score) were similar across most 
variables.  
Insert Table 3 about here 
Application of the item decision rules resulted in the removal of 25 items leaving 19 items. 
Collaborator review of these items raised the concern that many of the items related to function had 
been lost. The item decision rules were therefore applied to Group A and Group B separately 
resulting in one additional item to consider from Group A and ten from Group B (Table 4). Any 
patient comments for each of the 30 surviving items were carefully reviewed which led to the 
removal of five items (marked as ‘removed’ in the final column of Table 4). The wording of one item 
(issue 39) was changed from ‘Have you worried that you might lose your independence?’ to ‘Have 
you worried about becoming more dependent on others?’ as some patients pointed out that they 
were already somewhat dependent on others. The collaborators at each centre translated this item 
into their own language and then checked with 5-10 patients that the new version was acceptable. 
Item 31, ‘Have you felt hungry?’ (issue 1) was also removed because it is ambiguous whether this is 
positive or negative with respect to HRQOL. Appetite loss is covered by the QLQ-C30. 
 
Insert Table 4 about here 
The provisional module therefore has 24 items and is called the EORTC QLQ-CAX24. Five multi-item 
scales are proposed – food aversion, eating and weight-loss worry, eating difficulties, loss of control 
and physical decline and four – and four single items (Table 5). Adequate internal consistency and 
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convergent validity was demonstrated for three of the five scales. For the other two scales, eating 
difficulties and physical decline, the values fell slightly below the desired levels.  
 
Insert Table 5 about here 
 
 
Discussion 
Cachexia is a common condition in cancer patients with profound consequences. The EORTC QLQ-
CAX24 has been developed to be used in conjunction with the EORTC QLQ-C30 to assess HRQOL in 
this patient group. The development process followed a predefined set of guidelines and decision 
rules for inclusion of relevant issues. The module was developed with the help of cancer patients 
from nine countries at different stages of the cancer disease trajectory, from relatively soon after 
diagnosis to those approaching the end of life, and with differing numbers of S-NIS. Item selection 
was primarily based on the results and feedback from the patient participants. This study has shown 
that the QLQ-CAX24 is relevant, acceptable and applicable to patients with cancer cachexia. 
The issues included in the QLQ-CAX24 are consistent with the conceptual model we developed (20) 
from our review of the literature. The provisional module contains five scales and four single items. 
Further assessment of scale structure, using multi-trait scaling and factor analyses, along with 
possible modification, will occur in Phase 4 (international validation study). The Phase 4 study will 
also be used to explore differences in the HRQOL of patients with many and few S-NIS and it may be 
that the module is shortened if some items are not applicable across all patients. Information about 
the progress of Phase 4, and copies of the QLQ-CAX24 can be obtained from the EORTC Quality of 
Life Group website, http://groups.eortc.be/qol. 
Although there may be some modification to the QLQ-CAX24 after Phase 4,through a reduction in 
length and adjustment to the scale structure, it is now available for use in clinical trials. Whether 
clinicians and researchers should choose to use the QLQ-CAX24 or the FAACT, the only other 
instrument for the assessment of HRQOL in patients with cancer cachexia, will partly be determined 
by which of the core questionnaires from the EORTC and FACIT measurement systems is most 
applicable to their requirements (16, 27). An additional consideration is that the FAACT is a single 
scale whereas the QLQ-CAX24 comprises scales allowing more precise hypothesis testing. 
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Although the QLQ-CAX24 has been developed with and for patients with cancer cachexia, cachexia is 
a condition found in a number of other diseases, both chronic and acute (28). The items included in 
the QLQ-CAX24 may be applicable to patients with cachexia regardless of the underlying disease. 
With a relatively small amount of further development and testing, the QLQ-CAX24 may prove useful 
with patients who have cachexia as a result of a disease other than cancer.  
Limitations 
The limitations of the study include possible participation bias. As a formal cachexia assessment 
instrument is not currently available (29), patients were selected based on clinical judgement and 
because they met the consensus definition of cancer cachexia (1). However, use of a recruitment 
matrix ensured that the views of patients at different stages of cachexia, some of whom were 
nearing the end of life, were included. Patients with pre-cachexia were not included because of the 
difficulty in identifying this group clinically (30). 
Only European centres have contributed to the development of the QLQ-CAX24 so far. Non-
European centres, including North and South America, Japan and India, will be included in the Phase 
4 validation study. 
Conclusion 
In conclusion, the QLQ-CAX24 is a new cachexia-specific HRQOL questionnaire which has been 
developed for use with cancer patients in research and clinical practice. The questionnaire has been 
pilot tested and a provisional scale structure has been proposed. Full validation will be carried out in 
the final phase of development, when the provisional questionnaire is tested with a large number of 
patients in an international field study. This will allow the reliability and validity, the cross-cultural 
applicability and the psychometric properties of module to be assessed. 
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Table 1: Characteristics of patients participating in Phase 1 
 
 Phase 1a participants Phase 1b participants 
Age (years) 
Mean (SD)                                                   
Range 
 
63.5 (11.2)
43-87 
 
60.7 (11.9) 
31-82 
Number of males 12 (57.1) 9 (50.0) 
Country                           
Italy 
 
6 (28.6) 
 
6 (33.3) 
Norway 3 (14.3) 6 (33.3) 
Switzerland 7 (33.3) - 
UK 5 (23.8) 6 (33.3) 
Primary tumour                     
lung 
 
2 (9.5) 
 
2 (11.1) 
head & neck 1 (4.8) 2 (11.1) 
upper GI 5 (23.8) 5 (27.8) 
breast 4 (19.0) 1 (5.6) 
colorectal 3 (14.3) 2 (11.1) 
gynaecological 1 (4.8) - 
lymphoma 3 (14.3) 1 (5.6) 
male cancer - 1 (5.6) 
melanoma - 1 (5.6) 
thyroid 2 (9.5) - 
unknown origin  - 2 (11.1) 
brain - 1 (5.6) 
Disease stage                
local 
 
1 (4.8) 
 
2 (11.1) 
local advanced 5 (23.8) 4 (22.2) 
metastatic 15 (71.4) 12 (66.7) 
Cachexia type 
syndrome, few S-NIS 
 
5 (23.8) 
 
5 (27.8) 
refractory, few S-NIS 3 (14.3) 3 (16.7) 
syndrome, many S-NIS 8 (38.1) 8 (44.4) 
refractory, many S-NIS 5 (23.8) 2 (11.1) 
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Values in parentheses are percentages unless indicated otherwise. Abbreviations: SD, standard 
deviation; S-NIS, secondary nutrition impact symptoms 
Table 2: Number of patients in each cell of the Phase 3 sampling matrixa 
 
 Cachexia syndrome: 
Interview within 100 
days of cancer 
diagnosis 
Cachexia syndrome: 
Interview >100 days after 
cancer diagnosis 
Refractory 
cachexia: 
ECOG performance 
status 3 or 4 
Group A 
Symptom Checklist 
scaled score ≤25 
 
25 17 13 
Group B 
Symptom Checklist 
scaled score >25 
 
12 20 22 
 
Abbreviations: ECOG, Eastern Cooperative Oncology Group 
aTotal is less than 110 because one patient with cachexia syndrome, interviewed in the first 100 days 
after cancer diagnosis, did not complete a Symptom Checklist  
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Table 3: Characteristics of patients participating in Phase 3b 
 
 Whole Sample 
n=110 
Group A (low 
symptom 
checklist score) 
n=55 
Group B (high 
symptom 
checklist score) 
n=54 
Age (years)                                               Mean (SD) 
                                                                           Range 
62.9 (13.7) 
20-93 
62.5 (13.2) 
40-93 
63.4 (14.4) 
20-84 
Number of males 63 (57.3) 31 (56.4) 31 (56.4) 
Primary tumour                                                  lung 25 (22.7) 10 (18.2) 14 (25.9) 
head & neck 17 (15.5) 11 (20.0) 6 (10.9) 
upper GI 16 (14.5) 7 (12.7) 9 (16.4) 
breast 13 (11.8) 7 (12.7) 6 (10.9) 
colorectal 13 (11.8) 8 (14.5) 5 (9.1) 
gynaecological 8 (7.3) 5 (9.1) 3 (5.5) 
lymphoma 6 (5.5) 3 (5.5) 3 (5.5) 
male cancer 4 (3.6) 1 (1.8) 3 (5.5) 
kidney 3 (2.7) 1 (1.8) 2 (3.6) 
melanoma 3 (2.7) 1 (1.8) 2 (3.6) 
thyroid 1 (0.9) 0 (0.0) 1 (1.8) 
unknown origin  1 (0.9) 1 (1.8) 0 (0.0) 
One or more comorbidities 32 (29.1) 17 (30.9) 15 (27.3) 
Symptom Checklist scaled score         Mean (SD) 
                                                                           Range 
25.9 (15.4) 
0-74.5 
13.9 (7.5) 
0-23.5 
38.2 (10.9) 
25.5-74.5 
BMI                                                            Mean (SD) 
                                                          Range 
n 
21.3 (3.9) 
15.5-31.2 
109 
21.9 (3.9) 
16.0-31.2 
55 
20.8 (3.8) 
15.5-28.4 
53 
% WL in last 3 months                           Mean (SD) 
Range 
n 
7.7 (6.6) 
-7.3-23.4 
96 
8.0 (5.6) 
-6.7-22.1 
46 
7.4 (7.5) 
-7.3-23.4 
50 
% WL in last 6 months                           Mean (SD) 
Range 
n 
12.9 (7.6) 
-9.6-32.6 
102 
12.8 (6.6) 
-9.6-25.7 
51 
12.7 (8.4) 
-8.3-32.6 
50 
% WL from premorbidity                      Mean (SD) 
Range 
n 
18.2 (7.5) 
-6.9-45 
92 
17.4 (7.4) 
6.3-45.0 
43 
18.7 (7.6) 
-6.9-37.6 
48 
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ECOG performance status              0 7(6.4) 3 (5.5) 4 (7.3) 
1 25 (22.7) 13 (23.6) 12 (21.8) 
2 42 (38.2) 25 (45.5) 16 (29.1) 
3 29 (26.4) 11 (20.0) 18 (32.7) 
4 6 (5.5) 2 (3.6) 4 (7.3) 
Missing 1 (0.9) 1 (1.8) 0 (0.0) 
Toxicity level                                                     None 45 (40.9) 25 (45.5) 19 (34.5) 
Mild 36 (32.7) 20 (36.4) 16 (29.1) 
Severe 29 (26.4) 10 (18.2) 19 (34.5) 
Living alone 21 (19.0) 13 (23.6) 8 (14.5) 
Carer easily available 85 (77.3) 39 (70.9) 46 (83.6) 
Education beyond secondary school 46 (41.8) 24 (43.6) 22 (40.0) 
Previous employment level                    Unskilled 23 (20.9) 7 (12.7) 15 (27.3) 
Skilled manual 45 (40.9) 26 (47.3) 19 (34.5) 
Administrative 22 (20.0) 8 (14.5) 14 (25.5) 
Professional 17 (15.5) 12 (21.8) 5 (9.1) 
Missing 3 (2.7) 1 (1.9) 1 (1.8) 
 
Values in parentheses are percentages unless indicated otherwise. Abbreviations: SD, standard 
deviation; WL, weight loss; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group 
bNumber of patients in Group A and Group B added together is less than Whole Sample because one 
patient did not complete a Symptom Checklist and so could not be classified.  
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Table 4: Results from Phase 3 
Issue Samples meeting 
relevance & 
importance 
criteria  
Samples meeting 
floor & ceiling 
criteria 
Samples meeting 
prevalence 
criterion 
Deletion 
vs. 
Retention 
1. No hunger All 3 All 3 All 3 Delete 
(scoring 
ambiguity) 
2. Willing but not 
able to eat 
All 3 All 3 Whole sample & 
Group B 
Retain 
3. Taste changes All 3 All 3 Whole sample & 
Group B 
Retain 
4. Texture of food 
unpleasant 
Whole sample & 
Group B 
All 3 Whole sample & 
Group B 
Retain 
5. Put off eating by 
thought of food 
None All 3 Group B  Delete 
6. Put off eating by 
food smells 
Whole sample & 
Group B 
All 3 Group B  Retain 
7. Put off eating by 
quantity 
Group B  All 3 All 3 Retain 
8. Change in food 
preferences 
None All 3 Whole sample & 
Group B 
Delete 
9. Changeable 
appetite 
None All 3 All 3 Delete 
10. Missing past 
experiences 
Group B  All 3 Whole sample & 
Group B 
Delete 
(patient 
comments) 
11. Weight loss 
preventing usual 
activities 
All 3 All 3 All 3 Retain 
12. Too tired to eat Whole sample & 
Group B 
All 3 Group B  Retain 
13. Unable to eat 
because in pain 
All 3 All 3 Group B  Retain 
14. Feeling too full to 
eat 
All 3 All 3 All 3 Retain 
15. Difficulty drinking All 3 All 3 Group B  Retain 
16. Dry mouth All 3 All 3 All 3 Retain 
17. Difficulties 
chewing 
Whole sample & 
Group A 
All 3 None Delete 
18. Difficulties 
swallowing 
All 3 All 3 Group B  Retain 
19. Indigestion/heart
burn 
All 3 All 3 Group B  Retain 
20. Not eating as 
much 
All 3 All 3 Whole sample & 
Group B 
Retain 
21. Worried about 
weight loss 
All 3 All 3 All 3 Retain 
22. Thinks a lot about 
food and eating 
None All 3 Whole sample & 
Group B 
Delete 
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23. Outlook on future 
worsened 
Whole sample & 
Group A 
All 3 All 3 Delete 
(patient 
comments) 
24. Thinking about 
the ultimate 
result of weight 
loss 
All 3 All 3 All 3 Retain 
25. Mealtimes as 
social events 
Group A  All 3 All 3 Delete 
(patient 
comments) 
26. Feeling supported 
by others 
All 3 Whole sample & 
Group B 
None Delete 
27. Feeling pressured 
by others 
Whole sample  All 3 Whole sample & 
Group B 
Retain 
28. Concern about 
being a burden 
All 3 All 3 All 3 Retain 
29. Problem eating 
with others 
None All 3 None Delete 
30. Embarrassed by 
eating 
None Whole sample & 
Group B 
None Delete 
31. Embarrassed by 
weight loss 
Whole sample  All 3 None Delete 
32. Change in self-
identity upsetting 
None All 3 All 3 Delete 
33. Bothered by 
appearance 
All 3 All 3 All 3 Retain 
34. Change in role in 
life upsetting 
All 3 All 3 All 3 Delete 
(patient 
comments) 
35. Feeling physically 
less attractive 
Group B  All 3 Whole sample & 
Group B 
Delete 
(patient 
comments) 
36. Uncomfortable 
with sexual 
intimacy 
None All 3 None Delete 
37. No control over 
weight 
All 3 All 3 All 3 Retain 
38. Keeping things 
normal 
All 3 All 3 All 3 Retain 
39. Staying 
independent 
All 3 All 3 Whole sample & 
Group B 
Retain 
40. Forcing self to eat All 3 All 3 All 3 Retain 
41. Avoiding thinking 
about weigh loss 
None All 3 Whole sample & 
Group B 
Delete 
42. Acceptance of 
change in eating 
Group B  All 3 None Delete 
43. Inadequate 
information 
All 3 All 3 Group B  Retain 
44. Lack of support 
from health care 
professionals 
All 3 All 3 None Delete 
16 
 
 
Legend 
Samples: Group A - fewer secondary nutritional impact symptoms (S-NIS); Group B - more S-NIS 
symptoms; Whole sample - Group A and B combined. Relevance and importance criteria:  ≥60% 
patients rated the item as relevant and important (quite a bit or very much); floor and ceiling 
criteria: ≥10% patient responses for both response options one or two and three or four; prevalence 
criteria ≥50% patients reported the issue applies quite a bit or very much 
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Table 5: Issues included in the EORTC QLQ-CAX24 and hypothesised conceptual scales for QLQ-
CAX24 
Conceptual Scale Issues Cronbach’s 
alpha 
Item 
correlation 
with scale 
(range)
a
 
Food aversion Taste changes 
Texture of food unpleasant 
Put off eating by food smells 
Put off eating by quantity 
Feeling too full to eat 
0.72 0.41 to 0.53 
Eating and weight-loss 
worry 
Worried about weight loss 
Worried not eating enough 
Worried about ultimate result of 
weight loss 
0.74 0.52 to 0.60 
Eating difficulties Willing but not able to eat 
Difficulty drinking 
Difficulties swallowing 
0.62 0.32 to 0.49 
Loss of control Feeling pressured by others 
Concern about being a burden 
Bothered by appearance 
No control over weight 
Keeping things normal 
Staying independent 
0.79 0.43 to 0.66 
Physical decline Weight loss preventing usual 
activities 
Too tired to eat 
Unable to eat because in pain 
0.62 0.39 to 0.52 
4 single items Dry mouth 
Indigestion/heartburn 
Forcing self to eat 
Inadequate information 
N/A N/A 
a corrected for overlap  
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Figure 1: Stages of cancer cachexia 
 
 
Abbreviation: BMI Body-mass index 
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Figure 2: Symptom checklist 
Based on abridged Patient-Generated Subjective Global Assessment and Nutrition Impact Symptoms Checklist 
Symptom Checklist 
I have had the following problems that have kept me from eating enough during the past 
two weeks: 
 Not at All A Little Quite a Bit Very Much 
1. No appetite, just did not feel like eating 1 2 3 4 
2. Nausea 1 2 3 4 
3. Constipation 1 2 3 4 
4. Mouth sores (stomatitis) 1 2 3 4 
5. Things taste funny or have no taste 1 2 3 4 
6. Problems swallowing 1 2 3 4 
7. Abdominal/stomach pain 1 2 3 4 
8. Other pain: 
where?____________________________ 
1 2 3 4 
9. Vomiting 1 2 3 4 
10. Diarrhoea 1 2 3 4 
11. Dry mouth 1 2 3 4 
12. Smells bother me 1 2 3 4 
13. Feels full quickly 1 2 3 4 
14. Defecation after meals 1 2 3 4 
15. Shortness of breath 1 2 3 4 
16. Fatigue 1 2 3 4 
17. Other reason: 
what?_____________________________ 
1 2 3 4 
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Figure 3: Summary of EORTC QLQ-CAX24 Development 
 
aHCP interviews only  
Literature review 
68 issues 
Semi-structured patient interviews (n=21) 
Italy, Norway, Switzerland, UK 
64 issues (22 new) 
90 issues 
50 issues reviewed by 
patients (n=18) & HCPs (n=12) 
Italy, Norway, Switzerlanda, UK 
 
44 issues deleted 
Overlap with other issues: 32 
Not HRQOL issues: 9 
Overlap with QLQ-C30: 3 
 
4 additional issues 
Issues suggested by investigators: 3 
1 issue separated into 2 
 
Translation of preliminary CAX module (44 items) 
7 additional items 
4 issues separated into 9 items 
New items: 2 
13 issues deleted 
Patient feedback: 9 
Issue valence ambiguity: 2 
Moved to case report form: 2 
Semi-structured patients interviews (n=110) 
France, Germany, Greece, Italy, Norway, Poland, Sweden, UK 
EORTC QLQ-CAX24 
20 items deleted 
Not meeting criteria: 15 
Patient feedback: 4 
Scoring ambiguity: 1 
Phase 3 
Phase 1 
Phase 2 
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